Cinqaero is indicated as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.
MeSH: Asthma
Group: Other systemic drugs for obstructive airway diseases